Related Experiment Video
Updated: Jul 12, 2026
06:34
Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices
Published on: November 29, 2024
Gene therapy for mucopolysaccharidosis
Katherine P Ponder1, Mark E Haskins
1Washington University School of Medicine, Department of Internal Medicine, 660 South Euclid Avenue, St. Louis, MO 63110, USA. kponder@im.wustl.edu
Expert Opinion on Biological Therapy
|August 31, 2007
Summary
Gene therapy for mucopolysaccharidoses (MPS) shows promise. Different delivery methods, like viral vectors or stem cell transduction, aim to correct enzyme deficiencies, but safety remains a key concern for widespread therapeutic use.
Area of Science:
- Biochemistry
- Genetics
- Molecular Biology
Background:
- Mucopolysaccharidoses (MPS) are genetic disorders caused by deficiencies in lysosomal enzymes responsible for glycosaminoglycan degradation.
- Accumulation of glycosaminoglycans leads to progressive cellular damage and multi-systemic disease manifestations.
Purpose of the Study:
- To review current gene therapy strategies for mucopolysaccharidoses (MPS).
- To evaluate the efficacy and limitations of various gene delivery vectors and approaches in preclinical models.
- To highlight challenges and future directions for safe and effective MPS gene therapy.
Main Methods:
- Review of gene therapy approaches for MPS, including the use of adeno-associated virus (AAV), adenovirus, retrovirus, and plasmid vectors.
- Analysis of different vector administration routes: intravenous injection, hematopoietic stem cell transduction, and local delivery.
- Assessment of enzyme expression and therapeutic correction in various organs, particularly liver, spleen, and brain.
Main Results:
- Intravenous vector delivery primarily targets the liver and spleen, with variable correction in other tissues.
- Achieving therapeutic enzyme levels in the central nervous system often requires high systemic enzyme activity or direct brain delivery.
- Alternative strategies like hematopoietic stem cell transduction offer potential for broader tissue distribution.
Conclusions:
- Gene therapy presents a promising avenue for long-term treatment of MPS.
- Optimizing vector delivery and ensuring systemic enzyme distribution are crucial for widespread therapeutic benefits.
- Resolving safety concerns associated with gene therapy vectors is paramount for clinical translation in MPS treatment.
Related Concept Videos
01:23Glycosaminoglycans
Glycosaminoglycans (GAGs), also known as mucopolysaccharides, are long and linear polymers comprising of specific repeating disaccharides - the amino sugar that can be N-acetylglucosamine or N-acetylgalactosamine, and a uronic acid that is usually glucuronic acid or iduronic acid.
GAGS are found in the extracellular matrix of vertebrates, invertebrates, and bacteria. Due to their polar nature they attract water, and serve as excellent lubricants or shock absorbers in an animal body.
Hyaluronic...
GAGS are found in the extracellular matrix of vertebrates, invertebrates, and bacteria. Due to their polar nature they attract water, and serve as excellent lubricants or shock absorbers in an animal body.
Hyaluronic...
01:05Proteoglycans
Glycans, a class of complex heterogeneous molecules, can be covalently attached to proteins to form glycosylated proteins that regulate various physiological and pathological processes. Glycosylated proteins or glycoproteins comprise N-linked and O-linked oligosaccharides. O-glycosylation is the most common type of protein glycosylation. Here, glycans attach to the oxygen atom of the hydroxyl groups of Serine or Threonine residues. O-linked glycosylation occurs later in protein processing,...
01:24Cystic Fibrosis: Management
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic sinusitis...
Sinus disease and chronic sinusitis...
01:22Lysosomal Hydrolases
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
01:29Cardiomyopathy V: Interprofessional Care
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
01:26Peptic Ulcer Disease IV: Management
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current medication...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current medication...